Bristol Myers Squibb led a $237 million Series E for Pathos AI, valuing the company at roughly $3 billion as it scales its AI-driven drug development engine. The company says its Foundry platform deploys thousands of specialized agents to synthesize clinical data, genomics, and specimen information in near real time, with an emphasis on portfolio growth and milestone execution. Pathos plans to use the capital to advance multiple assets toward key development points, including JSKN-016, a TROP2/HER3 bispecific ADC intended for a registrational study. The financing also underscores how large pharma is underwriting AI-centric discovery platforms with dedicated datasets, with BMS participation reinforcing competitive pressure on AI-native biotech pipelines.